Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $27.63 and traded as low as $26.34. Kestra Medical Technologies shares last traded at $26.63, with a volume of 382,493 shares traded.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Evercore initiated coverage on Kestra Medical Technologies in a report on Tuesday, October 20th. They set an "outperform" rating and a $34.00 price objective for the company. Piper Sandler reiterated an "overweight" rating on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Wall Street Zen lowered shares of Kestra Medical Technologies from a "hold" rating to a "sell" rating in a research report on Sunday, November 8th. BTIG Research reissued a "buy" rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada set a $30.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.00.
Read Our Latest Report on Kestra Medical Technologies
Kestra Medical Technologies Price Performance
The business has a 50 day moving average of $27.63 and a 200 day moving average of $24.17. The company has a market cap of $1.59 billion, a PE ratio of -9.97 and a beta of 0.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The company had revenue of $30.97 million during the quarter. As a group, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.
Insider Activity
In other news, insider Traci S. Umberger sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total transaction of $2,718,000.00. Following the completion of the transaction, the insider directly owned 195,825 shares of the company's stock, valued at $5,322,523.50. The trade was a 33.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elizabeth Kwo sold 4,010 shares of Kestra Medical Technologies stock in a transaction on Monday, September 21st. The stock was sold at an average price of $24.26, for a total value of $97,282.60. Following the completion of the sale, the director directly owned 14,116 shares of the company's stock, valued at $342,454.16. The trade was a 22.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 251,456 shares of company stock valued at $7,173,746. 5.30% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Kestra Medical Technologies
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KMTS. Entropy Technologies LP bought a new stake in Kestra Medical Technologies during the 3rd quarter valued at approximately $698,000. Jump Financial LLC grew its holdings in Kestra Medical Technologies by 147.5% during the 3rd quarter. Jump Financial LLC now owns 53,800 shares of the company's stock valued at $1,522,000 after buying an additional 32,063 shares in the last quarter. Pathstone Holdings LLC purchased a new stake in Kestra Medical Technologies during the 3rd quarter valued at approximately $356,000. First Trust Advisors LP raised its position in shares of Kestra Medical Technologies by 352.1% during the third quarter. First Trust Advisors LP now owns 313,012 shares of the company's stock valued at $8,855,000 after buying an additional 243,775 shares during the last quarter. Finally, Global Retirement Partners LLC raised its position in shares of Kestra Medical Technologies by 56,300.0% during the third quarter. Global Retirement Partners LLC now owns 1,692 shares of the company's stock valued at $48,000 after buying an additional 1,689 shares during the last quarter.
About Kestra Medical Technologies
(
Get Free Report)
Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company's flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient's heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.